TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 30, 2026 - P1/2 | N=150 | Active, not recruiting | Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd. | Trial completion date: Nov 2026 ➔ Sep 2027 | Trial primary completion date: May 2026 ➔ Jun 2027
First-in-human • Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor
|